All News

RheumNow Podcast square

Sleep Apnea Smart Watches (10.13.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

Hard Decisions in RA (9.1.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
RheumNow Podcast square

Mono- and Oligo- are Different (8.18.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Read Article
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article
RheumNow Podcast square

English for the Biologically-Challenged (8.4.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article
RheumNow Podcast square

Scleroderma – Thick and Thin (6.30.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.

Read Article
#ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis -Anti-NT5c1A assoc with dysphagia -Anti-Ro52/TRIM21: female -Anti-VCP: male -Anti-NT5c1A + clinical markers: high accuracy in separating SIBM vs AIM Need longitudinal data for clusters to be meaningful @RheumNow https://t.co/fu0a074XAZ
Md Yuzaiful Md Yusof  ( View Tweet)
#ACR23 Abstr#2580 Could high-intensity resistance training improve outcomes in myositis? RCT showed 16 wks of training was tolerable, improved quality of life & functional capacity, without increasing disease activity/damage @RheumNow https://t.co/O1nP2x9C1L
Md Yuzaiful Md Yusof  ( View Tweet)
Don’t forget: 👉anti-HMGCR Ab in patients with immune mediated necrotizing myositis (may be assc with statins) 👉Anti-synthetase Ab assc with ILD, anti-synthetase syndrome #Rheum #BoardQuestion https://t.co/pBAADeR9ON

TheDaoIndex KDAO2011 ( View Tweet)

High mortality risk predictors in patients with anti-MDA5 dermatomyositis include: - rapidly progressive interstitial lung disease - anti-Ro52 antibody - age > 57 years (based on study of 126 MDA-5+ DM pts) https://t.co/VCyLhStFgX https://t.co/y3CyzOlwDt

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/VKsxT34lga https://t.co/VGaFmsYUrP

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM: 19 yoM w/ 3yr hx of Raynauds, periungual erythema. Nailfold capillaroscopy showed giant nailfold capillaries, branched & bushy neovascularized capillary loops & reduced capillary density; suggesting clinically amyopathic dermatomyositis https://t.co/Wvnp7wCajx

Links:

Dr. John Cush RheumNow ( View Tweet)

JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/0B1zzeqm1L

Links:

Dr. John Cush RheumNow ( View Tweet)

Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/3xL0ylJbcs https://t.co/Oerf0yI4Jg

Links:

Dr. John Cush RheumNow ( View Tweet)
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/CG9ClLHEW6 https://t.co/DPekHWjTsP

Links:

Dr. John Cush RheumNow ( View Tweet)
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few years @RheumNow https://t.co/Oh8sZlMzUt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×